Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 10/2003

01.10.2003 | Short Communication

Vitrectomy and trabeculectomy combined with interferon alpha treatment in Adamantiades-Behçet's disease: a case report

verfasst von: Lothar Krause, Friedrich Hoffmann, Christos C. Zouboulis, Michael H. Foerster

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Abstract

Background

Adamantiades-Behçet's disease is a multisystem disorder with recurrent oral and/or genital ulcerations, skin lesions, and ocular involvement. Eye involvement is a common manifestation that affects the patients' quality of life more than any other. Left untreated, it leads to blindness and often to loss of the eye through secondary complications such as phthisis or painful glaucoma.

Methods

Case report of a 24-year-old patient of Turkish descent living in Germany since his birth was admitted to our Department of Ophthalmology in 1999 because of visual loss in his right eye. He could only perceive light in that eye and evidenced total retinal detachment. In the left eye he had 20/20 vision but showed signs of retinal vascular inflammation and secondary glaucoma.

Results

Treatment with interferon alpha (9×106 I.U./3× week s.c.) and prednisolone (100 mg/d p.o.) led to complete regression of the acute inflammation within 2 weeks prior to operation. Vitrectomy was then successfully performed in the right eye under the therapy of interferon alpha (9×106 I.U./3× week s.c.) and 10 mg prednisolone p.o. The prednisolone therapy was stopped 1 week following operation. The failure of conservative glaucoma treatment necessitated trabeculectomy in the left eye. The patient has had no further recurrence for 4 years under monotherapy with interferon alpha (3×106 I.U./3× week s.c.).

Conclusion

Interferon alpha is a potent therapy for Adamantiades-Behçet's disease with ocular involvement. It also provides a basis for safe and reliable surgical interventions. There was no intra- or perioperative recurrence of inflammation, which is a common finding in these procedures.
Literatur
1.
Zurück zum Zitat Adamantiades B (1931) Sur un cas d'ìritis hypopyon recidivant. Ann Oculst 168:271–278 Adamantiades B (1931) Sur un cas d'ìritis hypopyon recidivant. Ann Oculst 168:271–278
2.
Zurück zum Zitat Alpsoy E, Durusoy C, Yilmaz E et al. (2002) Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 138:467–471PubMed Alpsoy E, Durusoy C, Yilmaz E et al. (2002) Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 138:467–471PubMed
3.
Zurück zum Zitat Bang D (1997) Treatment of Behçet's disease. Yonsei Med J 38:401–410PubMed Bang D (1997) Treatment of Behçet's disease. Yonsei Med J 38:401–410PubMed
4.
Zurück zum Zitat Behçet H (1937) Über rezidivierende, aphtöse, durch ein Virus verursachte Geschwüre im Mund, am Auge und an den Genitalien. Dermatol Wochenschr 105:1152–1157 Behçet H (1937) Über rezidivierende, aphtöse, durch ein Virus verursachte Geschwüre im Mund, am Auge und an den Genitalien. Dermatol Wochenschr 105:1152–1157
5.
Zurück zum Zitat Hamuryudan V, Özyazagan Y, Hizli N et al. (1997) Azathioprine in Behçet's syndrome. Arthritis Rheum 40:769–774PubMed Hamuryudan V, Özyazagan Y, Hizli N et al. (1997) Azathioprine in Behçet's syndrome. Arthritis Rheum 40:769–774PubMed
6.
Zurück zum Zitat Kötter I, Eckstein A, Stübiger N, Günaydin I, Zierhut M (1996) Therapy of ocular Behçet's disease with recombinant human interferon-alpha-2a. Rev Rheumatism (Engl Ed) 63:560 Kötter I, Eckstein A, Stübiger N, Günaydin I, Zierhut M (1996) Therapy of ocular Behçet's disease with recombinant human interferon-alpha-2a. Rev Rheumatism (Engl Ed) 63:560
7.
Zurück zum Zitat Kötter I, Eckstein AK, Stübiger N, Zierhut M (1998) Treatment of ocular symptoms of Behçet's disease with interferon-alpha-2a. Br J Ophthalmol 82:488–494PubMed Kötter I, Eckstein AK, Stübiger N, Zierhut M (1998) Treatment of ocular symptoms of Behçet's disease with interferon-alpha-2a. Br J Ophthalmol 82:488–494PubMed
8.
Zurück zum Zitat Krause L, Adler YD, Hoffmann F, Orfanos CE, Zouboulis CC, Foerster MH (1999) Treatment of ocular Adamantiades-Behçet's disease with interferon-alpha. Invest Ophth Vis Sci 41:371 Krause L, Adler YD, Hoffmann F, Orfanos CE, Zouboulis CC, Foerster MH (1999) Treatment of ocular Adamantiades-Behçet's disease with interferon-alpha. Invest Ophth Vis Sci 41:371
9.
Zurück zum Zitat Ozdemir O, Erkam N, Bakkaloglu A (1988) Results of pars plana vitrectomy in Behçet's disease. Ann Ophthalmol 20:35, 38PubMed Ozdemir O, Erkam N, Bakkaloglu A (1988) Results of pars plana vitrectomy in Behçet's disease. Ann Ophthalmol 20:35, 38PubMed
10.
Zurück zum Zitat Ozerturk Y, Bardak Y, Durmus M (2001) Vitreoretinal surgery in Behçet's disease with severe ocular complications. Acta Ophthalmol Scand 79:192–196CrossRefPubMed Ozerturk Y, Bardak Y, Durmus M (2001) Vitreoretinal surgery in Behçet's disease with severe ocular complications. Acta Ophthalmol Scand 79:192–196CrossRefPubMed
11.
Zurück zum Zitat Rizzi R, Bruno S, Dammacco R (1997) Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes. Int J Clin Lab Res 27:225–232 Rizzi R, Bruno S, Dammacco R (1997) Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes. Int J Clin Lab Res 27:225–232
12.
Zurück zum Zitat Stuebiger N, Koetter I, Deuter C, Zierhut M (2001) Morbus Behçet: Uveitis-Therapie mit Interferon α2a—prospektive klinische (Pilot-) Studie an 33 Patienten. Klin Monatsbl Augenheilkd 218:768–773CrossRefPubMed Stuebiger N, Koetter I, Deuter C, Zierhut M (2001) Morbus Behçet: Uveitis-Therapie mit Interferon α2a—prospektive klinische (Pilot-) Studie an 33 Patienten. Klin Monatsbl Augenheilkd 218:768–773CrossRefPubMed
13.
Zurück zum Zitat Wechsler B, Bodaghi B, Huong DL et al. (2000) Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 8:293–301CrossRefPubMed Wechsler B, Bodaghi B, Huong DL et al. (2000) Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 8:293–301CrossRefPubMed
14.
Zurück zum Zitat Yazici H, Barnes CG (1991) Practical treatment recommendations for pharmacotherapy of Behçet's syndrome. Drugs 42:796–804 Yazici H, Barnes CG (1991) Practical treatment recommendations for pharmacotherapy of Behçet's syndrome. Drugs 42:796–804
15.
Zurück zum Zitat Yazici H, Pazarli H, Barnes CG et al. (1990) A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 322:281–285PubMed Yazici H, Pazarli H, Barnes CG et al. (1990) A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 322:281–285PubMed
16.
Zurück zum Zitat Zouboulis CC (1999) Epidemiology of Adamantiades-Behçet's disease. Ann Med Interne 150:488–498 Zouboulis CC (1999) Epidemiology of Adamantiades-Behçet's disease. Ann Med Interne 150:488–498
17.
Zurück zum Zitat Zouboulis CC, Orfanos CE (1998) Treatment of Adamantiades-Behçet's disease with systemic interferon-alpha. Arch Dermatol 134:1010–1016CrossRefPubMed Zouboulis CC, Orfanos CE (1998) Treatment of Adamantiades-Behçet's disease with systemic interferon-alpha. Arch Dermatol 134:1010–1016CrossRefPubMed
Metadaten
Titel
Vitrectomy and trabeculectomy combined with interferon alpha treatment in Adamantiades-Behçet's disease: a case report
verfasst von
Lothar Krause
Friedrich Hoffmann
Christos C. Zouboulis
Michael H. Foerster
Publikationsdatum
01.10.2003
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 10/2003
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-003-0754-1

Weitere Artikel der Ausgabe 10/2003

Graefe's Archive for Clinical and Experimental Ophthalmology 10/2003 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.